KalVista Files 8-K on Financial Results & Operations
Ticker: KALV · Form: 8-K · Filed: Mar 25, 2026 · CIK: 0001348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: earnings, financial-results, 8-K, corporate-disclosure
TL;DR
**KalVista just dropped an 8-K with their latest financial results, so check it out!**
AI Summary
KalVista Pharmaceuticals, Inc. filed an 8-K on March 25, 2026, primarily disclosing its results of operations and financial condition under Item 2.02. This filing also included financial statements and exhibits under Item 9.01, specifically an EX-99.1 document. This matters to investors because it provides the latest financial performance data, which can influence stock valuation and future investment decisions for KalVista Pharmaceuticals (CIK: 0001348911).
Why It Matters
This filing provides crucial, up-to-date financial information that investors need to assess KalVista's current health and future prospects.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial results and does not inherently introduce new risks, but rather provides data to assess existing ones.
Analyst Insight
A smart investor would review the EX-99.1 exhibit and the detailed financial statements to understand KalVista's recent performance and assess its implications for future stock movements.
Key Numbers
- 0001193125-26-122784 — SEC Accession No. (unique identifier for this specific filing)
- 24916 — Size of 8-K document (indicates the length of the primary 8-K filing document)
- 45978 — Size of EX-99.1 document (indicates the length of the exhibit containing additional financial information)
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — the filer of the 8-K
- 0001348911 (company) — KalVista's CIK number
- 2026-03-25 (date) — the filing and period of report date
FAQ
What is the primary purpose of this 8-K filing by KalVista Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing, dated March 25, 2026, is to report on Item 2.02, 'Results of Operations and Financial Condition,' and Item 9.01, 'Financial Statements and Exhibits,' as indicated in the filing details.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on March 25, 2026, at 07:16:51.
What specific exhibit was included with this 8-K filing?
An exhibit labeled 'EX-99.1' (document type d127514dex991.htm) was included with this 8-K filing, which is typically used for press releases or other financial information.
What is KalVista Pharmaceuticals, Inc.'s CIK number and state of incorporation?
KalVista Pharmaceuticals, Inc.'s CIK number is 0001348911, and its state of incorporation is DE (Delaware).
What is the business address for KalVista Pharmaceuticals, Inc. as listed in the filing?
The business address for KalVista Pharmaceuticals, Inc. is 200 CROSSING BOULEVARD, FRAMINGHAM MA 01702, with a phone number of (857) 999-0075.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2026-03-25 07:16:51
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share KALV The Nasdaq
Filing Documents
- d127514d8k.htm (8-K) — 24KB
- d127514dex991.htm (EX-99.1) — 45KB
- 0001193125-26-122784.txt ( ) — 185KB
- kalv-20260325.xsd (EX-101.SCH) — 3KB
- kalv-20260325_lab.xml (EX-101.LAB) — 17KB
- kalv-20260325_pre.xml (EX-101.PRE) — 11KB
- d127514d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press release dated March 25, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: March 25, 2026 By: /s/ Brian Piekos Brian Piekos Chief Financial Officer